Table 1.
Patient Characteristics According to the Presence or Absence of Clonal Hematopoiesis
| Characteristic | A Total Cohort n = 110 |
B CH Negative n = 48 |
C CH Positive n = 62 |
P-value B vs Ca |
|---|---|---|---|---|
| Age at diagnosis, y | ||||
| Median (range) | 60 (3–79) | 54 (3–79) | 61 (17–76) | <0.001b |
| Age at CAR T-cell treatment, y | ||||
| Median (range) | 62 (18–80) | 58 (18–80) | 65 (21–79) | <0.001b |
| Sex | ||||
| Male, no. (%) | 77 (70.0) | 31 (65) | 46 (74) | |
| Female, no. (%) | 33 (30) | 17 (35) | 16 (26) | |
| Diagnosis | ||||
| LBCL, no. (%) | 88 (80) | 40 (83) | 48 (77) | |
| TFL, no. (%) | 6 (6) | 1 (2) | 5 (8) | |
| MCL, no. (%) | 11 (10) | 4 (8) | 7 (11) | |
| ALL, no. (%) | 5 (5) | 3 (6) | 2 (3) | |
| Ann-Arbor stage | 0.51 | |||
| I–II, no. (%) | 28 (25) | 13 (27) | 15 (24) | |
| III–IV, no. (%) | 72 (65.5) | 28 (58) | 44 (71) | |
| Missing data, no. (%) | 10 (9) | 7 (15) | 3 (5) | |
| Prior lines of therapy | ||||
| Median (range) | 4 (2–9) | 4 (2–8) | 4 (2–9) | |
| Autologous HSCT prior CAR T-cell treatment | 0.42 | |||
| Yes, no. (%) | 37 (33.6) | 14 (29) | 23 (37) | |
| No, no. (%) | 73 (66) | 34 (71) | 39 (63) | |
| CNS involvement prior CAR T-cell treatment | 0.26 | |||
| Yes, no. (%) | 26 (23.6) | 14 (29) | 12 (19) | |
| No, no. (%) | 84 (76) | 34 (71) | 50 (81) | |
| Remission prior CAR T-cell treatment (CR/PR vs SD/PD) |
0.02 | |||
| CR, no. (%) | 10 (9) | 4 (8) | 6 (10) | |
| PR, no. (%) | 22 (20) | 4 (8) | 18 (29) | |
| SD, no. (%) | 14 (13) | 4 (8) | 10 (16) | |
| PD, no. (%) | 63 (57) | 35 (73) | 28 (45) | |
| Missing data, no. (%) | 1 (1) | 1 (2) | 0 | |
| CAR T-cell product | ||||
| Axicabtagene-ciloleucel, no. (%) | 43 (39.0) | 19 (40) | 24 (39) | |
| Tisagenlecleucel, no. (%) | 56 (50.9) | 25 (52) | 31 (50) | |
| Brexucabtagene autoleucel, no. (%) | 11 (10) | 4 (8) | 7 (11) |
aCalculated with Fisher exact test, missing data were excluded.
bCalculated with Mann-Whitney U test.
.